Hormonal
Obesity is characterized by systemic chronic low-grade inflammation driven by adipose tissue-derived mediators (adipokines) and infiltrating immune cells, which contributes to insulin resistance and metabolic complications.
If you have excess abdominal fat, your body is likely in a state of chronic, low-grade inflammation that increases your risk for diabetes and heart disease. This is driven by hormones released from fat cells and immune cells invading fat tissue. Weight loss significantly lowers these inflammatory markers, reducing metabolic risk.
Low-grade inflammation is a characteristic of the obese state, and adipose tissue releases many inflammatory mediators... Obese people have higher circulating concentrations of many inflammatory markers than lean people do, and these are believed to play a role in causing insulin resistance and other metabolic disturbances.
Why this rating
The paper is a comprehensive review by ILSI Europe citing numerous human and animal studies, establishing a strong consensus on the mechanism.
Source
Dietary factors and low-grade inflammation in relation to overweight and obesity
Philip C. Calder et al. · British Journal Of Nutrition · 2011
DOI 10.1017/s0007114511005460
More from this paper
- Dietary patterns rich in whole grains, vegetables, fruits, and fish are associated with lower circulating concentrations of inflammatory markers, while saturated fats, trans fats, and high glycemic loads promote inflammation.Good
- Postprandial inflammation occurs after meals, particularly those high in glucose or fat, and is exaggerated in obese and diabetic individuals, but can be mitigated by antioxidants and specific dietary components.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →